Advances in treatment, particularly the combination of platinum-based chemotherapy (CT) with immune checkpoint inhibitors (ICPi) targeting programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1), have improved survival in advanced NSCLC patients [4]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.